4.90

2.00% -0.10

Silence Therapeutics Plc Adr (SLN)

Overview News Price History Discussions Forecast

Silence Therapeutics Plc Adr stock is traded at $4.90, with a volume of 44,336. It is down -2.00% in the last 24 hours and down -13.58% over the past month. Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Previous Close:

$5.00

Open:

$5.01

24h Volume:

44,336

Relative Volume:

0.16

Market Cap:

$233.80M

Revenue:

$31.37M

Net Income/Loss:

$-53.77M

P/E Ratio:

-3.3707

EPS:

-1.4537

Net Cash Flow:

$-49.02M

1W Performance:

+10.11%

1M Performance:

-13.58%

6M Performance:

-8.41%

1Y Performance:

+2.30%

1-Day Range:

$4.8766

$5.56

1-Week Range:

$4.375

$5.56

52-Week Range:

$1.97

$7.775

Silence Therapeutics Plc Adr Stock (SLN) Company Profile

Name

Silence Therapeutics Plc Adr

Sector

Healthcare (1117)

Industry

Biotechnology (619)

Phone

44-0-20-3457 6900

Address

12 HAMMERSMITH GROVE, LONDON

Employee

116

Twitter

Next Earnings Date

Latest SEC Filings

SLN's Discussions on Twitter

Compare SLN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLN Silence Therapeutics Plc Adr	4.9499	236.17M	31.37M	-53.77M	-49.02M	-1.4537
VRTX Vertex Pharmaceuticals Inc	485.71	121.15B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	785.50	82.43B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	828.96	52.25B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	330.68	44.59B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	366.48	40.07B	4.98B	69.60M	525.67M	0.5198

Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Goldman	Sell
Dec-02-24	Reiterated	BMO Capital Markets	Outperform
Sep-03-24	Initiated	Jefferies	Buy
Jan-31-24	Initiated	BMO Capital Markets	Outperform

Silence Therapeutics Plc Adr Stock (SLN) Latest News

Feb 15, 2026

Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $32.60 - Defense World

Feb 15, 2026

Feb 12, 2026

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat

Feb 12, 2026

Feb 10, 2026

Silence Therapeutics (NASDAQ:SLN) Shares Down 5.1%Here's What Happened - MarketBeat

Feb 10, 2026

Jan 31, 2026

Here's Why We're Watching Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation - Sahm

Jan 31, 2026

Jan 23, 2026

H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 By Investing.com - Investing.com India

Jan 23, 2026

H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75 - Investing.com

Jan 23, 2026

Jan 18, 2026

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Jan 18, 2026

Jan 15, 2026

Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7%Should You Sell? - MarketBeat

Jan 15, 2026

Silence Therapeutics (NASDAQ:SLN) Trading Down 0.7% – Should You Sell? - Defense World

Jan 15, 2026

Jan 10, 2026

Silence Therapeutics Insider Ups Holding During Year - Sahm

Jan 10, 2026

Jan 09, 2026

Comparing PMV Pharmaceuticals (NASDAQ:PMVP) & Silence Therapeutics (NASDAQ:SLN) - Defense World

Jan 09, 2026

Jan 02, 2026

Was Autonomix Medical Inc (AMIX)’s session last reading good? - uspostnews.com

Jan 02, 2026

Dec 29, 2025

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN

Dec 29, 2025

Dec 24, 2025

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of “Hold” from Analysts - Defense World

Dec 24, 2025

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Dec 24, 2025

Dec 22, 2025

Silence Therapeutics appoints CFO Rhonda Hellums to board of directors By Investing.com - Investing.com South Africa

Dec 22, 2025

Silence Therapeutics appoints CFO Rhonda Hellums to board of directors - Investing.com

Dec 22, 2025

Dec 15, 2025

Silence Therapeutics CEO Craig Tooman steps down By Investing.com - Investing.com India

Dec 15, 2025

Silence Therapeutics CEO Craig Tooman steps down - Investing.com

Dec 15, 2025

Dec 14, 2025

Frazier Life Sciences Management L.P. Decreases Holdings in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat

Dec 14, 2025

Dec 05, 2025

Does Silence Therapeutics Plc ADR (SLN) offer a good opportunity for investors? - setenews.com

Dec 05, 2025

Saturn V Capital Management LP Lowers Position in Silence Therapeutics PLC Sponsored ADR $SLN - MarketBeat

Dec 05, 2025

Nov 30, 2025

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Average Rating of "Hold" from Analysts - MarketBeat

Nov 30, 2025

Nov 27, 2025